Limited activity of metronomic cyclophosphamide and pembrolizumab for soft tissue sarcomas

Affiliations

¹ School of Medicine, Wayne State University, Detroit, MI, USA.
² Fred Hutchinson Cancer Research Center, Clinical Research Division, University of Washington, Division of Oncology, Seattle, WA, USA.

Editorial

Irvin C Lien et al. Transl Gastroenterol Hepatol. 2018.

. 2018 Jan 15:3:4.

doi: 10.21037/tgh.2017.12.09. eCollection 2018.

¹ School of Medicine, Wayne State University, Detroit, MI, USA.
² Fred Hutchinson Cancer Research Center, Clinical Research Division, University of Washington, Division of Oncology, Seattle, WA, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
Toulmonde M, Penel N, Adam J, Chevreau C, Blay JY, Le Cesne A, Bompas E, Piperno-Neumann S, Cousin S, Grellety T, Ryckewaert T, Bessede A, Ghiringhelli F, Pulido M, Italiano A. Toulmonde M, et al. JAMA Oncol. 2018 Jan 1;4(1):93-97. doi: 10.1001/jamaoncol.2017.1617. JAMA Oncol. 2018. PMID: 28662235 Free PMC article. Clinical Trial.

1. Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 2016;388:488-97. 10.1016/S0140-6736(16)30587-6 - DOI - PMC - PubMed
1. Iwai Y, Hamanishi J, Chamoto K, et al. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 2017;24:26. 10.1186/s12929-017-0329-9 - DOI - PMC - PubMed
1. Pollack SM, He Q, Yearley JH, et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer 2017;123:3291-304. 10.1002/cncr.30726 - DOI - PMC - PubMed
1. Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017;18:1493-501. 10.1016/S1470-2045(17)30624-1 - DOI - PMC - PubMed
1. Que Y, Xiao W, Guan YX, et al. PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis. J Cancer 2017;8:2018-25. 10.7150/jca.18683 - DOI - PMC - PubMed